The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer

Inclusion Criteria: * Patients aged 18 years or older * Patients must sign informed consent prior to study entry * Patients has Karnofsky performance status of more than 50% * No prior chemotherapy * Histologically or cytologically confirmed adenocarcinoma of the pancreas, locally advanced or metastatic disease or biliary cancer * No previous radiotherapy for locally advanced or metastases. * Hematopoietic: WBC \> 3000/mm2, Absolute neutrophile count \> 1500/mm2, Hemoglobin \> 9g/dl, Platelet count \> 100 000/mm2 Exclusion Criteria: * No intracerebral or meningeal metastases * Pregnant * Fertile patient must use effective contraception * No other serious medical condition or illness that would preclude study participation * Hepatic: Bilirubin greater than upper limit of normal(ULN) SGOT and SGPT \> 3.5 times upper limit of normal(ULN) alkaline phosphatase \> 6 times upper limit of normal(ULN) * More than 30 days since prior investigational therapy